Episodic Migraine

Enhanced Activation of the Spinal Trigeminal Nucleus in Chronic Migraine During Visual Stimulation

Enhanced Activation of the Spinal Trigeminal Nucleus in Chronic Migraine During Visual Stimulation

By

Patients with chronic migraine exposed to visual stimulation may have enhanced activity in the spinal trigeminal nucleus and the right superior colliculus compared with healthy individuals.

Comorbidity More Likely With Chronic Migraine vs Episodic Migraine

Comorbidity More Likely With Chronic Migraine vs Episodic Migraine

By

Researchers deployed a survey to determine the extent of pain, psychiatric, endocrine, and neurologic comorbidities in patients with chronic or episodic migraine.

Once-Monthly Erenumab Injections May Be Effective for Episodic Migraine Prophylaxis

Once-Monthly Erenumab Injections May Be Effective for Episodic Migraine Prophylaxis

By

A monthly subcutaneous injection of 70 mg erenumab may represent an effective prophylactic treatment for episodic migraine.

Erenumab Shows Promise in Treatment-Resistant Migraine

Erenumab Shows Promise in Treatment-Resistant Migraine

By

A recent study evaluated the safety and efficacy of erenumab in patients with episodic migraine who had experienced 2 to 4 previous preventive treatment failures, due to lack of efficacy or intolerable side effects.

Episodic Migraine-Related White Matter Hyperintensities Ipsilateral to Pain

Episodic Migraine-Related White Matter Hyperintensities Ipsilateral to Pain

By

Pain experienced by patients during episodic migraine is associated with the occurrence of white matter hyperintensities in the cerebral hemisphere ipsilateral to the pain side.

Episodic Migraines Possibly Prevented With Subcutaneous Galcanezumab

Episodic Migraines Possibly Prevented With Subcutaneous Galcanezumab

Researchers have found that monthly subcutaneous injection of galcanezumab significantly reduce migraine headache days.

Migraine Frequency Reduced With Erenumab, Fremanezumab

Migraine Frequency Reduced With Erenumab, Fremanezumab

By

Complete results from 2 phase 3 trials examining the effects of 2 humanized monoclonal antibodies in patients with episodic and chronic migraine were published simultaneously.

Episodic Migraines and Risk for Cardiovascular Disease: Treatment Implications

Episodic Migraines and Risk for Cardiovascular Disease: Treatment Implications

By

A large proportion of patients with episodic migraine have greater risk for cardiovascular disease with increasing age and subsequently have contraindications to treatment with triptan and ergot medications.

Chronic Daily Headache: New Subtype Identified in Case Series

Chronic Daily Headache: New Subtype Identified in Case Series

By

A recently published case series describes a new subtype of chronic daily headache that appears to be associated with elevated cerebrospinal fluid pressure.

Using Stress to Predict Risk of Migraine Even Before Predromal Symptoms

Using Stress to Predict Risk of Migraine Even Before Predromal Symptoms

By

Among individuals diagnosed with episodic migraines, stressful events can accurately predict an individual's risk of a headache, even before the onset of prodromal symptoms.

Hypothalamic Activation Greater in Chronic vs Episodic Migraine

Hypothalamic Activation Greater in Chronic vs Episodic Migraine

By

Examination of hypothalamic activity shows distinctly different patterns between episodic and chronic forms of migraine.

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

By

In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.

Sign Up for Free e-Newsletters